01:49 PM EDT, 07/08/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) shares were last seen up 4.7% after the company on Tuesday submitted its patented candidate breakthrough drug, Lucid-21-302, a new, first-in-class treatment for multiple sclerosis (MS), to the Innovative Licensing and Access Pathway (ILAP) Passport program in the United Kingdom, through its unit, Huge Biopharma Australia.

The ILAP program is "designed to accelerate the pace at which groundbreaking new medicines and treatments reach patients," the company said, reducing the time needed to develop and approve new treatments.

"We are excited about the possibility that the ILAP Program could accelerate drug development, regulatory approval and, most importantly, patient access to this exciting, new potential MS treatment in the UK," said Quantum Biopharma ( QNTM ) Vice-President, Scientific and Clinical Affairs Dr. Andrzej Chruscinski.

Shares of the company were last seen up $1.05 to $23.30 on the Canadian Securities Exchange

Price: 23.30, Change: +1.05, Percent Change: +4.72